SEARCH:   Advanced

Blood, 1 February 2007, Vol. 109, No. 3, pp. 874-885. Prepublished online as a Blood First Edition Paper on October 2, 2006; DOI 10.1182/blood-2006-07-012252. This Article Abstract Full Text (PDF) All Versions of this Article: blood-2006-07-012252v1 blood-2006-07-012252v2 109/3/874    most recent Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Rights and Permissions Citing Articles Citing Articles via HighWire Citing Articles via CrossRef Citing Articles via Google Scholar Google Scholar Articles by Falini, B. Articles by Mecucci, C. Search for Related Content PubMed PubMed Citation Articles by Falini, B. Articles by Mecucci, C. Related Collections Neoplasia Oncogenes and Tumor Suppressors Free Research Articles Review Articles Social Bookmarking                   What's this?  Previous Article  |  Table of Contents  |  Next Article  REVIEWS IN TRANSLATIONAL HEMATOLOGY Acute myeloid leukemia carrying cytoplasmic/mutated nucleophosmin (NPMc+ AML): biologic and clinical features Brunangelo Falini1, Ildo Nicoletti2, Massimo F. Martelli1, and Cristina Mecucci1 1 Institutes of Hematology and 2 Internal Medicine, University of Perugia, Perugia, Italy    Abstract Top Abstract Introduction Nucleophosmin (NPM1) gene and... Discovery of NPM1 mutations... Characteristics of NPM1... Nucleocytoplasmic traffic of... Altered nucleocytoplasmic... Role of NPM mutants... Pathologic and clinical features... Clinical impact of NPM1... Future perspectives Authorship References   The nucleophosmin (NPM1) gene encodes for a multifunctional nucleocytoplasmic shuttling protein that is localized mainly in the nucleolus. NPM1 mutations occur in 50% to 60% of adult acute myeloid leukemia with normal karyotype (AML-NK) and generate NPM mutants that localize aberrantly in the leukemic-cell cytoplasm, hence the term NPM-cytoplasmic positive (NPMc+ AML). Cytoplasmic NPM accumulation is caused by the concerted action of 2 alterations at mutant C-terminus, that is, changes of tryptophan(s) 288 and 290 (or only 290) and creation of an additional nuclear export signal (NES) motif. NPMc+ AML shows increased frequency in adults and females, wide morphologic spectrum, multilineage involvement, high frequency of FLT3-ITD, CD34 negativity, and a distinct gene-expression profile. Analysis of mutated NPM has important clinical and pathologic applications. Immunohistochemical detection of cytoplasmic NPM predicts NPM1 mutations and helps rationalize cytogenetic/molecular studies in AML. NPM1 mutations in absence of FLT3-ITD identify a prognostically favorable subgroup in the heterogeneous AML-NK category. Due to their frequency and stability, NPM1 mutations may become a new tool for monitoring minimal residual disease in AML-NK. Future studies should focus on clarifying how NPM mutants promote leukemia, integrating NPMc+ AML in the upcoming World Health Organization leukemia classification, and eventually developing specific antileukemic drugs.    Introduction Top Abstract Introduction Nucleophosmin (NPM1) gene and... Discovery of NPM1 mutations... Characteristics of NPM1... Nucleocytoplasmic traffic of... Altered nucleocytoplasmic... Role of NPM mutants... Pathologic and clinical features... Clinical impact of NPM1... Future perspectives Authorship References   Acute myeloid leukemia (AML) is clinically, cytogenetically, and molecularly heterogeneous.1 About 30% of cases carry recurrent chromosomal abnormalities that identify leukemia entities with distinct clinical and prognostic features,2 and 10% to 15% of AMLs have nonrandom chromosomal abnormalities. In cytogenetic analysis, 40% to 50% of AMLs show normal karyotype (AML-NK) and, biologically and clinically, are the most poorly understood group.1,3,4 Attempts to stratify AML-NK using gene microarrays5,6 succeeded in associating gene-expression patterns with differences in response to treatment, but no specific genetic subgroups emerged. Molecular analyses of AML-NK identified several mutations that target genes encoding for transcription factors (AML1 and CEBPA: 2%-3% and 15%-20% of cases, respectively),7–10 receptor tyrosine kinases (FLT3 and KIT: 25%-30% and 1%, respectively),11–13 and the RAS genes (10%),14 as well as a partial tandem duplication of MLL gene (MLL-PTD: 5%-10%).15–17 We discovered that nucleophosmin (NPM1) gene mutations target 50% to 60% of adult AML-NK.18 This is the most common genetic lesion described to date in adult de novo AML (about one third of patients).18 Since NPM1 mutations dislocate nucleophosmin into cytoplasm, we named this subgroup NPM-cytoplasmic positive (NPMc+) AML,18 and here we review its biologic and clinical features.    Nucleophosmin (NPM1) gene and protein Top Abstract Introduction Nucleophosmin (NPM1) gene and... Discovery of NPM1 mutations... Characteristics of NPM1... Nucleocytoplasmic traffic of... Altered nucleocytoplasmic... Role of NPM mutants... Pathologic and clinical features... Clinical impact of NPM1... Future perspectives Authorship References   Structure of gene and protein The NPM1 gene, mapping to chromosome 5q35 in humans, contains 12 exons19 (Figure 1A). It encodes for 3 alternatively spliced nucleophosmin isoforms: B23.1 (np_002511), B23.2 (np_954654), and B23.3 (np_001032827). View larger version (44K): [in this window] [in a new window]   Figure 1. The NPM1 gene encodes for a protein involved in multiple functions. (A) The NPM1 gene contains 12 exons. NPM1 is translated from exons 1 to 9 and 11 to 12. The portion encoding isoform B23.2 contains exons 1 to 10. In the protein, the N-terminus is characterized by a nonpolar domain responsible for oligomerization and heterodimerization. Functional nuclear export signal (NES) motifs and a metal-binding (MB) domain are present in this region. The central portion of the protein contains 2 acidic stretches (Ac) that are important for binding to histones, and a bipartite nuclear localization signal (NLS); this region confers ribonuclease activity. The C-terminus of the protein shows ribonuclease activity and contains basic regions involved in nucleic-acid binding. The latter are followed by an aromatic stretch, unique to NPM isoform 1, which contains 2 tryptophan residues (288 and 290), which are required for nucleolar localization of the protein (NoLS). (B) NPM is a nucleolar phosphoprotein that shuttles between the nucleus and cytoplasm. Shuttling plays a fundamental role in ribosome biogenesis, since NPM transports preribosomal particles. In cytoplasm, NPM binds to the unduplicated centrosome and regulates its duplication during cell division. Furthermore, NPM interacts with p53 and its regulatory molecules (ARF, Hdm2/Mdm2) influencing the ARF-Hdm2/Mdm2-p53 oncosuppressive pathway.   B23.1, the prevalent isoform,20 is a 294–amino acid protein of about 37 kDa, which shares a conserved N-terminal region with the other nucleophosmin isoforms and has multiple functional domains.21,22 The N-terminus portion contains a hydrophobic region,21,22 regulating self-oligomerization23 and NPM chaperone activity toward proteins, nucleic acids, and histones.24,25 In resting and proliferating cells, more than 95% of NPM is present as an oligomer26; both the nonpolar N-terminus region21 and multimeric state of NPM26 appear to be crucial for proper assembly of maturing ribosomes in the nucleolus. The middle portion of NPM contains 2 acidic stretches that are critical for histone binding25; the segment between the acidic stretches exerts ribonuclease activity.21 The C-terminal domain, with its basic regions involved in nucleic acid binding and ribonuclease activity,21,22 is followed by an aromatic short stretch encompassing tryptophans 288 and 290, which are critical for NPM binding to nucleolus.27 B23.1 is also equipped with a bipartite nuclear localization signal (NLS),21,22 leucine-rich nuclear export signal (NES) motifs,28,29 and several phosphorylation sites regulating its association with centrosomes30 and subnuclear compartments.31,32 In immunocytochemical analysis, B23.1 shows restricted nucleolar localization.20 B23.2, a truncated isoform, lacks the last 35 C-terminal amino acids of B23.1 (containing the nucleolar-binding domain) and is found in tissues at very low levels. In immunocytochemical analysis, B23.2 is located in nucleoplasm.33 Little information is available on the B23.3 isoform, which consists of 259 amino acids. Expression and functions of NPM protein Nucleophosmin is a highly conserved phosphoprotein that is ubiquitously expressed in tissues.34 It is one of the most abundant of the approximately 700 proteins identified to date in the nucleolus by proteomics.35,36 Although the bulk of NPM resides in the granular region of the nucleolus,36,37 it shuttles continuously between nucleus and cytoplasm,38,39 as proven by interspecies heterokaryon assays. NPM nucleocytoplasmic traffic is strictly regulated, since important NPM functions, including transport of ribosome components to the cytoplasm and control of centrosome duplication, are closely related to its ability to actively mobilize into distinct subcellular compartments.28,29 Here, we briefly discuss some of the major functions of NPM that have been recognized so far (Figure 1B). NPM plays a key role in ribosome biogenesis providing the necessary export signals and chaperoning capabilities that are required to transport components of the ribosome from nucleus to cytoplasm. A major role of NPM is to mediate, through a Crm1-dependent mechanism, nuclear export of the ribosomal protein L5/5S rRNA subunit complex.29 Other elements that implicate NPM in the processing and/or assembly of ribosomes are its nucleocytoplasmic shuttling properties and intrinsic RNAse activity,40 and the ability to bind nucleic acids,41 to process pre-RNA molecules,42 and to act as a chaperone,24 thus preventing protein aggregation in the nucleolus during ribosome assembly.23 Because it can directly access maturing ribosomes and potentially regulate the protein translational machinery,29 NPM seems to play a central role in balancing protein synthesis, and cell growth and proliferation. This view concurs with evidence that closely correlates NPM overexpression with cell proliferation43; for example, in bone marrow, NPM positivity progressively decreases as cells mature from proerythroblasts to normoblasts and from promyelocytes to neutrophils (B.F., personal observation, January 2005). Moreover, NPM overexpression promotes survival and recovery of hematopoietic stem cells under stress conditions44; high NPM levels in malignant cells promote aberrant cell growth by enhancing ribosome machinery. Conversely, inhibition of NPM shuttling or NPM loss block protein translation and produce cell-cycle arrest.29 NPM also maintains genomic stability,45,46 controlling DNA repair47 and centrosome duplication48 during mitosis. NPM associates with the unduplicated centrosome in resting cells and dissociates from it after CDK2-cyclinE–mediated phosphorylation on threonine 199,49 thus enabling proper chromosome duplication. NPM reassociates with centrosomes at the mitotic spindle during mitosis as a result of phosphorylation on serine 4 by PLK150 and NEK2A.51 NPM seems to protect from centrosome hyperamplification as its inactivation causes unrestricted centrosome duplication and genomic instability,45,52 with increased risk of cellular transformation. Finally, NPM interacts with the oncosuppressors p53 and p19Arf and their partners (ie, Hdm2/Mdm2), thus controlling cell proliferation and apoptosis.53 (1) Interaction with p53. NPM regulates p53 levels and activity. A functional link exists between nucleolar integrity, NPM, and p53 stability,54,55 since stimuli inducing cellular stress (eg, UV radiation or drugs interfering with rRNA processing) lead to loss of nucleolar integrity, relocation of NPM from nucleolus to nucleoplasm, and p53 activation.55,56 Nucleoplasmic NPM increases p53 stability by binding to, and inhibiting, Hdm2/Mdm257 (a p53 E3-ubiquitin ligase), although "nucleolar stress" can also activate p53 in an Hdm2/Mdm2-independent fashion.58,59 Thus, under stress conditions, the nucleolus functions as a "stress-sensor" with NPM playing a key role in potentiating p53-dependent cell-cycle arrest.57 NPM-p53 cross talk may also involve proteins that are downstream targets of p53 (eg, GADD45).60 (2) Interaction with ARF. In cultured unstressed cells, most NPM and ARF colocalize in the nucleolus, in high-molecular-weight complexes containing other nucleolar proteins.61 The NPM-ARF interaction helps stabilize both proteins, since ARF influences NPM polyubiquitination62 and NPM protects ARF from degradation.46,63 The functional significance of NPM and ARF interactions is still in debate.64 There is evidence that ARF targets NPM into nucleoli for degradation,62 that the ARF-NPM complex sequesters Hdm2/Mdm2 into the nucleolus thereby activating p53 in the nucleoplasm,65 that ARF impedes NPM shuttling, thereby producing cell-cycle arrest in a p53-independent fashion,66 and that NPM sequesters ARF into the nucleolus, impairs ARF-Hdm2/Mdm2 association, and inhibits ARF's p53-dependent activation.67 Despite these uncertainties, NPM and ARF activities appear closely coordinated and regulate cell proliferation and apoptosis65 through precise subnuclear compartmentalization.68 In response to cellular stress, NPM and ARF are redistributed to the nucleoplasm.68 Competition between Hdm2/Mdm2 and NPM for ARF binding promotes formation of NPM-Hdm2/Mdm2 and ARF-Hdm2/Mdm2 binary complexes and strongly activates the p53 pathway.69 Thus, through its nucleolar association with NPM, ARF may directly access ribosome function to inhibit cell growth, and via its nucleoplasmic interaction with Hdm2/Mdm2 and ARF-BP1,70 it may regulate the p53 cell-cycle pathway.    Discovery of NPM1 mutations in AML Top Abstract Introduction Nucleophosmin (NPM1) gene and... Discovery of NPM1 mutations... Characteristics of NPM1... Nucleocytoplasmic traffic of... Altered nucleocytoplasmic... Role of NPM mutants... Pathologic and clinical features... Clinical impact of NPM1... Future perspectives Authorship References   NPM1 is translocated to several partner genes in various hematopoietic malignancies,71 including CD30+ anaplastic large-cell lymphoma with t(2;5),72 the rare myelodysplasia/AML with t(3;5),73 and exceptional cases of promyelocytic leukemia with t(5;17).74 Translocations create chimeric genes encoding for fusion proteins (NPM-ALK,72 NPM-MLF1,73 and NPM-RAR74), which form heterodimers with wild-type NPM (NPMwt) and promote cellular transformation. Since proper NPM function is closely dependent on its levels in different cell compartments, we wondered whether NPM fusion proteins have a different subcellular distribution to NPMwt and whether this finding could be exploited for diagnostic purposes. In the late 1980s, we generated monoclonal antibodies against fixative-resistant epitopes of NPM protein34 to investigate NPM subcellular expression in anaplastic large-cell lymphoma carrying the NPM-ALK fusion protein compared with normal tissues. We found that, because of NPM-ALK chimeric protein, this lymphoma was associated with NPM expression in cytoplasm75 instead of in the nucleolus as in normal tissues.34 Reasoning that detection of aberrant cytoplasmic NPM might provide a simple way of immunoscreening routine bioptic samples for potential NPM1 gene alterations, we extended our immunohistochemical investigations to a range of human tumors, including leukemias. In 1999, we observed our first AML cases with cytoplasmic NPM but no known NPM fusion proteins, and named them NPMc+ AML to distinguish them from NPMc– AML, which showed the expected nucleus-restricted NPM expression. Subsequently, in 591 AML patients enrolled in the GIMEMA/AML12 EORTC trial, we observed cytoplasmic NPM is mutually exclusive of major chromosomal abnormalities, closely associates with normal karyotype, and has distinctive biologic and clinical features.18 These findings led us to hypothesize that an as-yet-unidentified genetic lesion of NPM1 gene underlayed NPMc+ AML, and indeed gene sequencing revealed mutations at exon 12.18    Characteristics of NPM1 mutations Top Abstract Introduction Nucleophosmin (NPM1) gene and... Discovery of NPM1 mutations... Characteristics of NPM1... Nucleocytoplasmic traffic of... Altered nucleocytoplasmic... Role of NPM mutants... Pathologic and clinical features... Clinical impact of NPM1... Future perspectives Authorship References   NPM1 mutations are reliably identified by various molecular biology techniques,76,77 which also allow simultaneous detection of NPM1 and FLT3-ITD or CEBPA mutations78,79 (all prognostically relevant in AML-NK10,80–83). Immunohistochemical detection of cytoplasmic NPM in AML is predictive of NPM1 mutations.84 The main advantages of immunohistochemistry are simplicity, low cost, and ability to correlate cytoplasmic NPM with morphology and topographic distribution of leukemic cells. Moreover, immunohistochemistry is the first-choice technique for detecting NPM1 mutations in cases of dry-tap or small biopsies (eg, skin involvement in myeloid sarcoma85), and also helps rationalize cytogenetic/molecular studies in AML.84 The choice of technique for detecting NPM1 mutations at diagnosis may be based on the investigator's experience, costs, available equipment, application of bone marrow trephine for AML diagnosis, among other factors. Immunohistochemistry is not suitable for monitoring minimal residual disease in NPMc+ AML. Specificity of NPM1 mutations NPM1 mutations are AML specific since other human neoplasms consistently show nucleus-restricted NPM expression.18 They have been sporadically detected in chronic myeloproliferative disorders (5/200 cases investigated; 2.5%).86,87 All 5 cases were chronic myelomonocytic leukemias and 4 quickly progressed to overt AML in less than 1 year, suggesting they represented M4 or M5 AMLs with marked monocytic differentiation (often targeted by NPM1 mutations18,80). NPM1 mutations were found in only 2 (5.2%) of 38 myelodysplastic patients.88 However, caution is needed when defining a case as "NPM1-mutated myelodysplastic syndrome" since NPMc+ AML frequently shows multilineage involvement and dysplastic features.89 NPM1 mutations closely associate with de novo AML, as AML secondary to myeloproliferative disorders/myelodysplasia and therapy-related AML rarely show cytoplasmic NPM.18 Types, frequency, and stability of NPM1 mutations A polymorphism of nucleotide T deletion at position 1146 in the NPM1 3'-untranslated region has been reported in 60% to 70% of AMLs and in healthy volunteers.81,90 NPM1 mutations are characteristically heterozygous and retain a wild-type allele. In children with AML, their incidence ranges from 2.1% in Taiwan90 to 6.5% in Western countries,91,92 accounting for 9% to 26.9% of all childhood AML-NK.90–92 In about 3000 adult AML patients, the frequency of NPM1 mutations ranged between 25% and 35%,80–83,90,93,94 accounting for 45.7% to 63.8% of adult AML-NK.80–83,90,93,94 This suggests the molecular pathogenesis of AML-NK is different in adults and children. Except for 2 cases involving the splicing donor site of NPM1 exon 995 and exon 11,96 mutations are restricted to exon 1218,80–83,93,94 (Figure 2). The most common NPM1 mutation, which we named mutation A,18 is a duplication of a TCTG tetranucleotide at position 956 to 959 of the reference sequence (GenBank accession number NM_002520) and accounts for 75% to 80% of cases. Mutations B and D are observed in about 10% and 5% of NPMc+ AML; other mutations are very rare (Figure 2). View larger version (104K): [in this window] [in a new window]   Figure 2. List of exon 12 NPM1 mutations so far identified in AML patients. Red coloring indicates nucleotides inserted by mutations; green, leucine-rich NES motif; violet, tryptophan (W) residues; L, leucine; C, cysteine; V, valine; M, methionine; and F, phenyl-alanine. Mutations A to F refer to those we originally identified.18 Mutations E to H refer to those we identified in childhood AML.91 Mutations J to Q refer to those subsequently identified in Falini et al.84 Mutations Gm to Qm refer to those we identified in the protocol 99 of the German AML cooperative group.80 Mutations 1, 3, 4, 6, 7, 12, 13, 10, and 14 are according to Dohner et al.81 Mutation I* is according to Verhaak et al.82 *NM_002520. Mutations G, I, H, and J are according to Suzuki et al.93   Alterations of the NPM1 gene appear more stable than those of FLT3 gene.93 Loss of NPM1 mutations at relapse is rare and may be due either to emergence of a different leukemic clone or inability to detect mutations because few leukemic blasts are infiltrating the marrow.90 In some cases, loss of NPM1 mutations was associated with change from normal to abnormal karyotype.90,93 AML patients with a germ-line NPM1 gene at diagnosis do not appear to acquire NPM1 mutations during the course of disease, suggesting that mutations play a scarce role in disease progression.90 Relationship between NPM1 mutations, karyotype, and other mutations Cytoplasmic NPM closely associates with normal karyotype (Figure 3A) and is mutually exclusive of recurrent genetic abnormalities,18 as confirmed by NPM1 mutational analysis of thousands of AML patients.80–83,91,93,94 Chromosomal abnormalities observed in a minority of NPMc+ AMLs (14%)18 are probably secondary because (1) they are similar, in type and frequency, to secondary chromosomal changes occurring in AML with recurrent genetic abnormalities97; (2) cells with an abnormal karyotype represent subclones within the leukemic population with normal karyotype18; and (3) these abnormalities occasionally occur at relapse in patients with AML-NK at diagnosis (B.F., unpublished observations, September 2005). View larger version (31K): [in this window] [in a new window]   Figure 3. NPM1 mutations closely associate with AML-NK and FLT3-ITD. (A) Pie chart showing cytogenetic alterations in adult AML and frequency of NPM1 gene mutations in AML with normal karyotype (AML-NK). (B) Pie chart showing relationship between NPM1 mutations and FLT3-ITD in AML-NK.   Several studies80–83,93 confirmed our original observation that NPMc+ AML is preferentially targeted by FLT3-ITD18 (Figure 3B). NPM1 and FLT3-TKD correlated in some studies,80,81,93 but not in others.18,82 Thiede et al83 found NPM1 mutations are primary events that precede acquisition of FLT3-ITD or other mutations. MLL-PTD rarely coincides with cytoplasmic/mutated NPM.18 Some authors80,81 reported no difference in frequency of CEBPA mutations in NPM1-mutated versus NPM1-unmutated AML-NK, while Chou et al90 found a negative correlation between NPM1 and CEBPA mutations. KIT and NRAS mutations were not significantly associated with NPM1 mutations.80,81 KRAS mutations were reported in 5 of 8 AML with NPM1 mutations.82 Unsurprisingly, TP53 mutations rarely occur in NPMc+ AML,93 as they mostly associate with karyotypic abnormalities,98,99 while NPM1 mutations are typical of AML-NK.    Nucleocytoplasmic traffic of wild-type NPM Top Abstract Introduction Nucleophosmin (NPM1) gene and... Discovery of NPM1 mutations... Characteristics of NPM1... Nucleocytoplasmic traffic of... Altered nucleocytoplasmic... Role of NPM mutants... Pathologic and clinical features... Clinical impact of NPM1... Future perspectives Authorship References   Although NPMwt is a nucleocytoplasmic shuttling protein,38 its expression is restricted to the nucleolus.34,37 Explanation comes from analysis of NPM functional domains (Figure 4 top). The NLS signal drives NPM from cytoplasm to nucleoplasm, where it is translocated to the nucleolus through its nucleolar-binding domain, particularly tryptophans 288 and 290.27 Nuclear export of NPM (and of proteins in general) is mediated by the evolution-conserved Crm1 (also called exportin 1),100,101 the export receptor of proteins containing leucine-rich NES motifs with the generally accepted loose consensus L-x(2,3)-(LIVFM)-x(2,3)-L-x-(LI),102 a core of closely spaced leucines or other large hydrophobic amino acids. Two such highly conserved NES motifs have been identified in the NPMwt protein: one with the sequence I-xx-P-xx-L-x-L within residues 94 to 10228 and another at the N-terminus within amino acids 42 to 61, with leucines 42 and 44 as critical nuclear export residues.29 However, despite the NES motifs, NPM remains localized in nucleoli (Figure 4 middle and bottom panels). Thus, in physiologic conditions, nuclear import of NPMwt greatly predominates over export (Figure 4 top panel), since NPMwt's NES motifs exhibit the general property of NES motifs (ie, weak interaction with Crm1).103,104 Knowledge of how NPMwt nucleocytoplasmic traffic is regulated at the steady state is fundamental to understanding the molecular mechanisms underlying aberrant cytoplasmic NPM expression in AML.18 View larger version (28K): [in this window] [in a new window]   Figure 4. NPM, a shuttling protein, is mainly localized in the nucleolus. (Top) Mechanism of nucleocytoplasmic traffic of NPM wild-type (NPMwt). Green boxes indicate NPMwt protein; red circles, tryptophan residues; NES motif, nuclear export signal motif; and NLS, nuclear localization signal. The nuclear import of NPM (arrows) greatly predominates over the nuclear export (dotted arrow). Thus, NPM is mainly localized in the nucleolus. (Middle) Confocal analysis of NIH-3T3 cells expressing enhanced green fluorescent protein (eGFP)–NPMwt fusion protein. The bulk of NPMwt (green) colocalizes in nucleoli with C23/nucleolin (red), as revealed using a specific antibody. Images were collected with a Zeiss LSM 510 confocal microscope (Zeiss, Jena, Germany) using a Plan Apochromat 100x/1.4 NA oil objective and the LSM 5 software (Zeiss) for image acquisition. An Alexa 543-conjugated secondary antibody (Molecular Probes, Eugene, OR) was used for C23/nucleolin staining; nuclei were stained with To-Pro3 (Molecular Probes). Three-dimensional reconstruction of the confocal images and electronic cuts of nucleus and nucleoli to analyze the subcellular distribution of NPMwt (green) and C23 (red) proteins were performed with Imaris software (Bitplane, Zurich, Switzerland).      Altered nucleocytoplasmic traffic of nucleophosmin in NPMc+ AML Top Abstract Introduction Nucleophosmin (NPM1) gene and... Discovery of NPM1 mutations... Characteristics of NPM1... Nucleocytoplasmic traffic of... Altered nucleocytoplasmic... Role of NPM mutants... Pathologic and clinical features... Clinical impact of NPM1... Future perspectives Authorship References   In NPMc+ AML, aberrant cytoplasmic NPM localization, which is easily detected by immunohistochemistry (Figure 5), is caused by 2 mutation-related alterations at the C-terminus of NPM leukemic mutants105: (1) generation of an additional leucine-rich NES motif,106 reinforcing Crm1-dependent nuclear export of mutated NPM proteins105; and (2) loss of tryptophan residues 288 and 290 (or residue 290 alone)18, which determine NPM nucleolar localization.27 Both alterations are crucial for perturbing NPM mutant traffic105 (Figure 6). View larger version (123K): [in this window] [in a new window]   Figure 5. Cytoplasmic NPM and multilineage involvement in NPMc+ AML. (Top, left) Myeloid sarcoma (skin, paraffin section). Nuclear plus aberrant cytoplasmic expression of NPM is seen in leukemic blasts. Normal residual vessel endothelial cells show the expected nucleus-restricted NPM expression (arrow). Immunostaining with monoclonal antibody 376 that recognizes both wild-type and mutated NPM (alkaline phosphatase anti–alkaline phosphatase [APAAP] technique; hematoxylin counterstaining; image was collected using an Olympus BX51 microscope and a UPlanApo 40x0.85 NA objective). (Top, right) NPMc+ AML (bone marrow biopsy, paraffin section). Cytoplasmic-restricted expression of mutant NPM protein in leukemic cells (arrow). A normal residual megakaryocyte is negative (double arrows). Immunostaining with a polyclonal antibody (Sil-A) that recognizes mutated but not wild-type NPM (APAAP technique; hematoxylin counterstaining; image was collected using an Olympus BX51 microscope and a UPlan FL 100x/1.3 NA oil objective). (Bottom, left) NPMc+ AML with multilineage involvement (bone marrow biopsy, image was collected using an Olympus BX51 microscope and a UplanApo 40x/0.85 NA objective). Double APAAP/immunoperoxidase staining for NPM (blue) and glycophorin (brown). Aberrant cytoplasmic expression of NPM is seen in proerythroblasts (arrow), megakaryocytes (double arrows), and myeloid blasts surrounding a blood vessel (asterisk). (Bottom, right) Higher magnification (image was collected using an Olympus BX51 microscope and a UPlan FL 100x/1.3 NA oil objective) from a different field of the same case. Proerythroblasts are strongly NPMc+ (blue) and weakly positive or negative for glycophorin (brown) (long arrow), while more mature erythroid precursors show nucleus-restricted NPM(blue)/strong surface glycophorin (brown) (short arrow). Double arrows indicate a NPMc+/glycophorin-negative megakaryocyte. A myeloid blast is positive for cytoplasmic NPM (blue) and negative for surface glycophorin (arrowhead).   View larger version (53K): [in this window] [in a new window]   Figure 6. Mechanism of perturbed NPM nucleocytoplasmic traffic in NPMc+ AML. (A) Cytoplasmic accumulation of NPM is NES-dependent. OCI-AML3 cell line carrying the NPM1 mutation A shows cytoplasmic (and nucleolar) positivity for NPM (green) (top, left). NPM is relocated into the nucleus after exposure to the Crm1 inhibitor leptomycin B (top, right). Cytoplasmic accumulation of NPM is tryptophan dependent. In NIH-3T3 cells, NPM mutant A is relocated from cytoplasm (green, bottom, left) into nucleoli (green, bottom right), after the 2 tryptophans (W) are reinserted at positions 288 and 299. Images were collected with a Zeiss LSM 510 confocal microscope using a Plan Apochromat 100x/1.4 NA oil objective and LSM 5 software for image acquisition. Nuclei were stained with propidium iodide (Molecular Probes). Three-dimensional reconstruction of the confocal images and electronic cuts of cells were performed with Imaris software. (B) Hypothetical mechanism of altered nucleocytoplasmic traffic of NPM mutant A and NPMwt. Green boxes indicate NPMwt protein; blue boxes, mutated NPM protein; red circles, tryptophan residues; black circles, mutated tryptophans; magenta boxes, NES motif; and NLS, nuclear localization signal.   Role of the additional C-terminus NES motif Specific exportin-1/Crm1-inhibitors107 (leptomycin-B and ratjadones) block cytoplasmic NPM accumulation, demonstrating that export of NPM mutants is NES dependent105 (Figure 6A top panels). How can we reconcile this finding with the observation that NPMwt, despite the presence of physiologic NES motifs,28,29 is restricted to nucleolus? Comparative analysis of artificial and leukemic NPM mutants provides the answer. Artificial NPMwt mutants lacking tryptophans 288 and 290 delocalize from nucleolus to nucleoplasm but do not accumulate into cytoplasm,27,28 due to the weak activity of the physiologic NES motifs; a similar picture is observed with the C-terminus truncated B23.2 isoform.33 In contrast, NPM leukemic mutants, which also lack C-terminus tryptophan(s), accumulate in the cytoplasm, since the new C-terminus NES motif acts as the additional force causing their overexport from nucleus to cytoplasm.105 Role of C-terminal tryptophans The C-terminus NES motif is, however, insufficient in itself, for nuclear export of NPM mutants105 because reinserting residues 288 and 290 (which are both critical for nucleolar binding27) relocates NPM mutants to nucleoli (Figure 6A bottom panels). More than 95% of NPM leukemic mutants lack tryptophans 288 and 290; the others retain tryptophan 288. Despite this difference, all mutants are aberrantly dislocated in the cytoplasm, implying that their nuclear export occurs even when tryptophan 288 is present. The explanation comes from analysis of the relationship between mutated tryptophans and types of NES motif at the C-terminus of leukemic mutants.105 Mutations of both tryptophans are usually associated with the most common NES motif (ie, L-xxx-V-xx-V-x-L); retention of tryptophan 288 is always associated with variants of this NES motif (ie, replacement of valine at the second position with leucine, phenyl-alanine, cysteine, or methionine).105 Therefore, to ensure NPM mutants are dislocated into cytoplasm, variant NES motifs likely need to be more efficient than L-xxx-V-xx-V-x-L, so as to counterbalance the action of tryptophan 288, which drives mutants to the nucleolus.27 That NES motifs may differ in their activity, influencing the ability of a given protein to be exported from the nucleus more or less efficiently, is a known phenomenon,108,109 which may also apply to NPM leukemic mutants. A hypothetical scheme of NPM nucleocytoplasmic traffic in NPMc+ AML is shown in Figure 6B. NPM mutants retain the NLS and can, therefore, enter the nucleus. Their capability to bind nucleoli is hindered completely (when both tryptophans are mutated) or partially (when only tryptophan 290 is altered). The additional C-terminus NES motif (L-xxx-V-xx-V-x-L if both tryptophans are mutated, or a variant NES motif if tryptophan 288 is retained) probably renders the mutants more available for binding to Crm1 in nucleoplasm. Under these circumstances, the NES-Crm1–mediated nuclear export of NPM mutants is more efficient than nuclear import and they accumulate in cytoplasm. There is now evidence that NPM mutants recruit NPMwt from nucleoli and delocalize it into nucleoplasm and cytoplasm,105,110 perhaps altering its functions. Recruitment occurs through the N-terminal dimerization domain that is conserved in all NPM mutants, allowing them to form heterodimers with NPMwt, as occurs between NPMwt and NPM fusion proteins.71,111,112 NPM also interacts with ARF and delocalizes it into cytoplasm.110,113    Role of NPM mutants in leukemogenesis Top Abstract Introduction Nucleophosmin (NPM1) gene and... Discovery of NPM1 mutations... Characteristics of NPM1... Nucleocytoplasmic traffic of... Altered nucleocytoplasmic... Role of NPM mutants... Pathologic and clinical features... Clinical impact of NPM1... Future perspectives Authorship References   NPM1 belongs to a new category of genes that function both as oncogenes and tumor-suppressor genes,114 depending on gene dosage, expression levels, interacting partners, and compartmentalization. NPM1 appears implicated in promoting cell growth, as its expression increases in response to mitogenic stimuli and above-normal amounts are detected in highly proliferating and malignant cells. On the other hand, since NPM contributes to growth-suppressing pathways through its interaction with ARF, loss of NPM expression or function can contribute to tumorigenesis. At present, no experimental models exist for NPMc+ AML. In NPM knock-out mice, NPM is involved in control of primitive hematopoiesis (especially erythropoiesis), and NPM is haploinsufficient for the control of proper centrosome duplication, resulting in genomic instability and development of a hematologic syndrome reminiscent of human myelodysplasia.45 In NPMc+ AML, since one NPM allele is mutated and NPM mutants dislocate the NPMwt encoded by the uninvolved allele into cytoplasm, one might argue that blasts show a form of NPM haploinsufficiency. However, NPMc+ AML is characterized by normal karyotype as NPM mutants are still effective in binding to, and controlling, centrosome duplication. Furthermore, NPM1 mutations are extremely rare in human myelodysplasia, being characteristically associated with de novo AML. Therefore, other mechanisms, probably related to inherent NPM mutant properties, may operate in humans to promote leukemic transformation. Cytoplasmic NPM may contribute to AML development by inactivating ARF, a critical antioncogene.115 In NIH-3T3 fibroblasts engineered to produce a zinc-inducible ARF protein, human leukemic NPM mutant A delocalizes NPMwt and ARF from nucleoli to cytoplasm,110 resulting in reduced p53-dependent (Hdm2/Mdm2 and p21cip1 induction) and p53-independent (ARF-induced sumoylation of NPM and Hdm2/Mdm2) ARF activities.110 When complexed with NPM mutant, ARF stability was greatly compromised and the p53-dependent cell-cycle arrest at the G1/S boundary was appreciably lower.113 ARF is only one of the potential targets of NPM mutants, and new molecules are expected to be found that could interact with NPM mutants and contribute to leukemogenesis. A hypothetical scheme of the molecular events underlying NPMc+ AML is shown in Figure 7. View larger version (35K): [in this window] [in a new window]   Figure 7. Hypothetical mechanism leading to NPMc+ AML.      Pathologic and clinical features of NPMc+ AML Top Abstract Introduction Nucleophosmin (NPM1) gene and... Discovery of NPM1 mutations... Characteristics of NPM1... Nucleocytoplasmic traffic of... Altered nucleocytoplasmic... Role of NPM mutants... Pathologic and clinical features... Clinical impact of NPM1... Future perspectives Authorship References   NPMc+ AML shows a wide morphologic spectrum.18 However, NPM1 mutations are more frequent in M4 and M5 FAB categories,18,80,81 and in AML with prominent nuclear invaginations ("cuplike" nuclei).116 More than 95% of NPMc+ AMLs are CD34–.18 Involvement of several cell lineages (myeloid, monocytic, erythroid, and megakaryocytic but not lymphoid)89 (Figure 5) is another distinctive, apparently intrinsic feature of NPMc+ AML that is independent of additional genetic alterations, such as FLT3-ITD. High frequency of multilineage involvement is somewhat surprising since NPMc+ AML is usually a de novo leukemia,18 and multilineage involvement is mainly associated with secondary leukemias.117 The blast count is higher in NPM-mutated than NPM–germ-line AML-NK,81,83 and rises with concomitant FLT3-ITD83 and LDH serum levels.81 NPM1 mutations correlate with extramedullary involvement, mainly gingival hyperplasia and lymphadenopathy,81 possibly because this extramedullary dissemination pattern is mostly seen with M4 and M5 AML,2 which are frequently targeted by NPM1 mutations.80,81 Platelet counts are higher in NPM-mutated than NPM–germ-line AML-NK.81,83 Of interest, bone marrow biopsies from NPMc+ AML (especially M4) frequently show increased number of megakaryocytes carrying mutated NPM and exhibiting dysplastic features.89 These findings suggest that megakaryocytes with NPM1 mutations retain a certain capacity for thrombocytic differentiation. NPM1 mutations are more frequent in female patients,80,81,83 strangely, as AML incidence is higher in males.83 This appears to be specific for NPM1 mutations, as a similar association is not seen for FLT3-ITD,83 which is also common in AML-NK. To date, only the 5q syndrome has been identified as a prevalent genetic alteration in females.118 Therefore, sex-specific differences might underlie the mechanism of NPMc+ AML development.    Clinical impact of NPM1 mutations Top Abstract Introduction Nucleophosmin (NPM1) gene and... Discovery of NPM1 mutations... Characteristics of NPM1... Nucleocytoplasmic traffic of... Altered nucleocytoplasmic... Role of NPM mutants... Pathologic and clinical features... Clinical impact of NPM1... Future perspectives Authorship References   Analysis of mutated/cytoplasmic NPM has important clinical applications. Response to therapy and prognostic value of NPM1 mutations After induction therapy, AML-NK carrying mutated/cytoplasmic NPM shows a higher complete remission rate than AML-NK without NPM1 mutations.18,80,83,93 Dohner et al81 found NPM1 mutation status is not an independent predictor for responsiveness to chemotherapy, because the best complete remission rate was observed only in the NPM1-mutated/FLT3-ITD–negative group, while the lowest response rate occurred in AML patients carrying both mutations. In 4 large European studies80–83 on more than 1000 AML-NKs, NPM1 mutations in the absence of FLT3-ITD identified a subgroup of patients with favorable prognosis. Notably, younger AML patients81 carrying NPM1 mutations without concomitant FLT3-ITD showed approximately 60% probability of survival at 5 years, that is, similar to long-term outcomes in AML carrying core-binding factor (CBF)119,120 or AML-NK with CEBPA mutations.121 In a donor versus no-donor comparison, the favorable prognostic group of NPM-mutated/FLT3-ITD–negative patients did not benefit from allogeneic stem cell transplantation.81 Thus, 2 "dueling" mutations122 act in AML-NK, because NPM1 and FLT3-ITD are, respectively, associated with good and bad prognosis. In patients with both mutations, FLT3-ITD–induced antiapoptotic and proproliferative pathways, especially via STAT5, might dominate the leukemic phenotype,123 explaining why 2 other groups,93,94 which did not stratify patients according to NPM1 and FLT3-ITD mutations, could not document differences in survival in NPM1-mutated cases. These studies emphasize the value of comprehensive molecular genetic screening in AML-NK, so as to improve risk stratification. It is unclear why NPM1-mutated/FLT3-ITD–negative patients respond reasonably well to therapy. Nucleoplasmic and cytoplasmic recruitment of NPMwt mediated by the NPM mutants might interfere with its functions. NPMwt protects hematopoietic cells from p53-induced apoptosis in conditions of cellular stress124; the level of genotoxic stress appears to regulate this effect.56 It is tempting to speculate that NPM mutants fail to protect cells and render them more susceptible to chemotherapy-induced high-level genotoxic stress. Of interest, daunorubicin-induced dislocation of NPMwt into nucleoplasm is associated with increased apoptosis.125 Monitoring of minimal residual disease Monitoring of minimal residual disease in AML-NK is hampered by the lack of reliable molecular markers. FLT3-ITD can be used for this purpose,11 but is detected in only about 30% of AML-NK.11,12 Since NPM1 mutations appear more stable than FLT3-ITD over the course of disease90,93 and occur in 50% to 60% of AML-NK,18,80–83 they may become a new tool for monitoring minimal residual disease. Preliminary results using a highly-sensitive real-time quantitative polymerase chain reaction (PCR) assay126 are encouraging but need to be validated in large clinical trials. Classification of leukemias Identification of NPMc+ AML impacts on the current World Health Organization (WHO) classification of AML,2 which encompasses 4 major categories: (1) AML with recurrent genetic abnormalities; (2) AML with multilineage dysplasia; (3) therapy-related AML; and (4) AML "not otherwise characterized." The latter bin category (currently subclassified according to slightly modified FAB criteria) accounts for 60% to 70% of de novo adult AML, including AML-NK and, therefore, NPMc+ AML. Our observation that the wide morphologic spectrum of NPMc+ AML derives from various combinations, at diverse ratios, of NPMc+ cells of different lineages (all belonging to the leukemic clone)89 question the value of FAB criteria for subclassifying "AML not otherwise characterized." The frequent finding of multilineage dysplasia in NPMc+ AML89 also raises doubts as to whether dysplasia is a reproducible criterion for assigning a case to WHO category 3. When updating WHO classification, we propose the term "AML not otherwise characterized" should be restricted to AML for which no genetic lesions have as yet been identified, and NPMc+ AML be provisionally considered as a separate entity, because of its high frequency and distinctive clinical and biologic features. Correct definition of the heterogeneous WHO AML categories 3 and 4 and their prognostic significance will require a more genetically oriented approach, including systematic chromosome banding analyses and screening for the prognostically relevant mutations (FLT3, CEBPA, and NPM1).    Future perspectives Top Abstract Introduction Nucleophosmin (NPM1) gene and... Discovery of NPM1 mutations... Characteristics of NPM1... Nucleocytoplasmic traffic of... Altered nucleocytoplasmic... Role of NPM mutants... Pathologic and clinical features... Clinical impact of NPM1... Future perspectives Authorship References   In spite of the remarkable progress achieved in biologic, diagnostic, and clinical characterization of NPM1 mutations since their first identification in early 2005,18 several important issues still remain to be explored. Although multilineage involvement points to derivation from a common myeloid or an earlier progenitor without the ability to differentiate into lymphoid lineages,89 the exact cell of origin of NPMc+ AML remains unknown. How does the NPMc+ AML cell of origin correlate with the recently revised road map for adult blood lineage development?127 In NPMc+ AML, how can we reconcile consistent CD34 negativity with up-regulation of HOX genes involved in stem-cell maintenance?82,128 What are the characteristics of leukemic stem cells in NPMc+ AML? These issues need to be addressed by analyzing flow-sorted progenitor populations and their engraftment potential in mice. How mutated NPM contributes to leukemogenesis still remains elusive. What we know at present could well be only part of the picture since NPM is an extremely eclectic molecule that is involved in multiple functions; others could well be identified in the future. Analysis of rare mutations occurring in NPM1 exons other than 1295,96 and the close relationship between tryptophan mutations and type of NES motif at NPM mutants C-terminus105 suggest the main aim of mutations is to place NPM in cytoplasm. One might infer that aberrant NPM localization in cytoplasm is, in some way, essential for transforming normal hematopoietic cells into leukemic blasts. Since very low levels of NPMwt (due to shuttling activity) are physiologically present in cytoplasm, the amount of NPM mutant that accumulates in cytoplasm may also be crucial for transforming activity. Thus, the goal of NPM1 mutations appears to be to export mutants into cytoplasm at the maximum efficient dose. Interference of the mutants with key functions of NPMwt and oncosuppressor ARF through their recruitment into cytoplasm may play a role in transforming activity, but one cannot discount that mutant NPM may interfere with the functions of other, as yet unidentified, proteins in the nucleus or cytoplasm. Mass spectrometry analysis may help characterize complexes formed by NPM mutants and these putative partners. The role of mutated NPM in leukemogenesis needs to be addressed in experimental models, which, due to close association of FLT3-ITD and NPM1 mutations in clinical practice,18,80–83 will also need to investigate whether FLT3-ITD plays a cooperative role (Figure 7). The NPM1 gene is an appealing target for therapy. Retargeting NPM from cytoplasm to its physiologic site (eg, nucleolus) is challenging because the NES motif and mutated tryptophan(s) at the NPM mutant C-terminus constitute 2 obvious obstacles.105 Analysis of differences in the 3-dimensional structure of the C-terminus of NPM mutants and NPMwt may lead to designing small molecules that can interfere with the abnormal NPM mutant traffic. However, efforts to pharmacologically target NPM might be hindered by the need to tread a very fine line in regulating its function so as to prevent the detrimental consequences of underfunctioning or overfunctioning. In fact, according to expression levels and gene dosage, NPM1 functions both as oncogene and tumor-suppressor gene114 and partial functional loss and aberrant overexpression both lead, through separate mechanisms, to abnormal cell growth. Several clinical issues yet need to be addressed. Immunohistochemistry (detection of cytoplasmic NPM) should be integrated with cytogenetics/fluorescence in situ hybridization (FISH)/molecular studies, to achieve maximum rationalization of biologic investigations in AML.84 As NPM1 mutations without FLT3-ITD identify a good prognostic subgroup, mutational studies should, in the future, be used to stratify risk in the heterogeneous category of AML-NK.18,80–83,129 Linking NPM1 mutations to good prognosis raises other clinically important questions. Does the prognostic value of mutated NPM1 apply to AML patients older than 60 years who are recognized as a poor prognostic category? Should adult NPM1-mutated/FLT3-ITD–negative AML-NK patients be exempted from allogeneic stem cell transplantation in first-line therapy,130 as is current practice for AMLs carrying t(8;21) or Inv(16)? Can we exploit FLT3 inhibitors to reverse NPM1-mutated/FLT3-ITD–positive patients into the more prognostically favorable category of NPM1 mutated/FLT3-ITD negative? Which molecular mechanism underlies the sensitivity of NPMc+ AML to chemotherapy? Does NPMc+ AML show selective sensitivity to any known chemotherapeutic agents? Can we exploit quantitative detection of NPM1-mutated copies126 to predict patients with long-term survival? Future prospective clinical trials and availability of a human cell line (OCI-AML3) carrying cytoplasmic/mutated NPM131 for drug testing should help provide answers.    Authorship Top Abstract Introduction Nucleophosmin (NPM1) gene and... Discovery of NPM1 mutations... Characteristics of NPM1... Nucleocytoplasmic traffic of... Altered nucleocytoplasmic... Role of NPM mutants... Pathologic and clinical features... Clinical impact of NPM1... Future perspectives Authorship References   Contribution: B.F. had the original idea, which, inspired by his immunohistochemical studies on ALK-positive anaplastic large-cell lymphoma, led to the discovery of NPM cytoplasmic/mutated acute myeloid leukemia (NPMc+ AML); B.F. is also the head of the project on NPM in acute myeloid leukemia; I.N. carried out the confocal microscopy studies; M.F.M. analyzed clinical data of NPMc+ AML patients; C.M. was involved in the study of NPM1 mutations. All authors contributed to writing the paper. Conflict-of-interest disclosure: B.F. and C.M. applied for a patent on clinical use of NPM mutants and have a financial interest in the patent. Correspondence: Brunangelo Falini, Institute of Hematology, Policlinico, Monteluce, 06122 Perugia, Italy; e-mail: faliniem{at}unipg.it; Cristina Mecucci, Institute of Hematology, Policlinico, Monteluce, 06122 Perugia, Italy; e-mail: crimecux{at}unipg.it.    Acknowledgments   This work was supported by the Associazione Italiana per la Ricerca sul Cancro (AIRC). We are indebted to Niccolò Bolli, Maria Paola Martelli, Arcangelo Liso, Roberto Rosati, Paolo Gorello, Barbara Bigerna, Alessandra Pucciarini, Roberta, Pacini, Alessia Tabarrini, and Roberta Mannucci for generating some of the data described in the paper. We would also like to thank Claudia Tibidò for her excellent secretarial assistance and Dr Geraldine Anne Boyd for her help in editing this paper.    Footnotes   Submitted July 10, 2006; accepted September 11, 2006. Prepublished online as Blood First Edition Paper, October 2, 2006 DOI: 10.1182/blood-2006-07-012252    References Top Abstract Introduction Nucleophosmin (NPM1) gene and... Discovery of NPM1 mutations... Characteristics of NPM1... Nucleocytoplasmic traffic of... Altered nucleocytoplasmic... Role of NPM mutants... Pathologic and clinical features... Clinical impact of NPM1... Future perspectives Authorship References   Gilliland DG, Jordan CT, Felix CA. The molecular basis of leukemia. Hematology (Am Soc Hematol Educ Program) 2004:80–97. Jaffe E, Harris N, Stein H, Vardiman J. Pathology and genetics of tumours of hematopoietic and lymphoid tissues. 2001;Lyon France IARC Press. Grimwade D, Walker H, Oliver F, et al. The importance of diagnostic cytogenetics on outcome in AML: analysis of 1,612 patients entered into the MRC AML 10 trial: The Medical Research Council Adult and Children's Leukaemia Working Parties. Blood 1998; 92:2322–2333.[Abstract/Free Full Text] Marcucci G, Mrozek K, Bloomfield CD. Molecular heterogeneity and prognostic biomarkers in adults with acute myeloid leukemia and normal cytogenetics. Curr Opin Hematol 2005; 12:68–75.[CrossRef][Medline] [Order article via Infotrieve] Bullinger L, Dohner K, Bair E, et al. Use of gene-expression profiling to identify prognostic subclasses in adult acute myeloid leukemia. N Engl J Med 2004; 350:1605–1616.[Abstract/Free Full Text] Valk PJ, Verhaak RG, Beijen MA, et al. Prognostically useful gene-expression profiles in acute myeloid leukemia. N Engl J Med 2004; 350:1617–1628.[Abstract/Free Full Text] Roumier C, Fenaux P, Lafage M, Imbert M, Eclache V, Preudhomme C. New mechanisms of AML1 gene alteration in hematological malignancies. Leukemia 2003; 17:9–16.[CrossRef][Medline] [Order article via Infotrieve] Pabst T, Mueller BU, Zhang P, et al. Dominant-negative mutations of CEBPA, encoding CCAAT/enhancer binding protein-alpha (C/EBPalpha), in acute myeloid leukemia. Nat Genet 2001; 27:263–270.[CrossRef][Medline] [Order article via Infotrieve] Frohling S, Schlenk RF, Stolze I, et al. CEBPA mutations in younger adults with acute myeloid leukemia and normal cytogenetics: prognostic relevance and analysis of cooperating mutations. J Clin Oncol 2004; 22:624–633.[Abstract/Free Full Text] Leroy H, Roumier C, Huyghe P, Biggio V, Fenaux P, Preudhomme C. CEBPA point mutations in hematological malignancies. Leukemia 2005; 19:329–334.[CrossRef][Medline] [Order article via Infotrieve] Schnittger S, Schoch C, Dugas M, et al. Analysis of FLT3 length mutations in 1003 patients with acute myeloid leukemia: correlation to cytogenetics, FAB subtype, and prognosis in the AMLCG study and usefulness as a marker for the detection of minimal residual disease. Blood 2002; 100:59–66.[Abstract/Free Full Text] Thiede C, Steudel C, Mohr B, et al. Analysis of FLT3-activating mutations in 979 patients with acute myelogenous leukemia: association with FAB subtypes and identification of subgroups with poor prognosis. Blood 2002; 99:4326–4335.[Abstract/Free Full Text] Beghini A, Ripamonti CB, Cairoli R, et al. KIT activating mutations: incidence in adult and pediatric acute myeloid leukemia, and identification of an internal tandem duplication. Haematologica 2004; 89:920–925.[Abstract/Free Full Text] Kiyoi H, Naoe T, Nakano Y, et al. Prognostic implication of FLT3 and N-RAS gene mutations in acute myeloid leukemia. Blood 1999; 93:3074–3080.[Abstract/Free Full Text] Schnittger S, Kinkelin U, Schoch C, et al. Screening for MLL tandem duplication in 387 unselected patients with AML identify a prognostically unfavorable subset of AML. Leukemia 2000; 14:796–804.[CrossRef][Medline] [Order article via Infotrieve] Dohner K, Tobis K, Ulrich R, et al. Prognostic significance of partial tandem duplications of the MLL gene in adult patients 16 to 60 years old with acute myeloid leukemia and normal cytogenetics: a study of the Acute Myeloid Leukemia Study Group Ulm. J Clin Oncol 2002; 20:3254–3261.[Abstract/Free Full Text] Steudel C, Wermke M, Schaich M, et al. Comparative analysis of MLL partial tandem duplication and FLT3 internal tandem duplication mutations in 956 adult patients with acute myeloid leukemia. Genes Chromosomes Cancer 2003; 37:237–251.[CrossRef][Medline] [Order article via Infotrieve] Falini B, Mecucci C, Tiacci E, et al. Cytoplasmic nucleophosmin in acute myelogenous leukemia with a normal karyotype. N Engl J Med 2005; 352:254–266.[Abstract/Free Full Text] Chang JH and Olson MO. Structure of the gene for rat nucleolar protein B23. J Biol Chem 1990; 265:18227–18233.[Abstract/Free Full Text] Wang D, Umekawa H, Olson MO. Expression and subcellular locations of two forms of nucleolar protein B23 in rat tissues and cells. Cell Mol Biol Res 1993; 39:33–42.[Medline] [Order article via Infotrieve] Hingorani K, Szebeni A, Olson MO. Mapping the functional domains of nucleolar protein B23. J Biol Chem 2000; 275:24451–24457.[Abstract/Free Full Text] Namboodiri VM, Akey IV, Schmidt-Zachmann MS, Head JF, Akey CW. The structure and function of Xenopus NO38-core, a histone chaperone in the nucleolus. Structure 2004; 12:2149–2160.[Medline] [Order article via Infotrieve] Yung BY and Chan PK. Identification and characterization of a hexameric form of nucleolar phosphoprotein B23. Biochim Biophys Acta 1987; 925:74–82.[Medline] [Order article via Infotrieve] Szebeni A and Olson MO. Nucleolar protein B23 has molecular chaperone activities. Protein Sci 1999; 8:905–912.[Medline] [Order article via Infotrieve] Okuwaki M, Matsumoto K, Tsujimoto M, Nagata K. Function of nucleophosmin/B23, a nucleolar acidic protein, as a histone chaperone. FEBS Lett 2001; 506:272–276.[CrossRef][Medline] [Order article via Infotrieve] Chan PK and Chan FY. Nucleophosmin/B23 (NPM) oligomer is a major and stable entity in HeLa cells. Biochim Biophys Acta 1995; 1262:37–42.[Medline] [Order article via Infotrieve] Nishimura Y, Ohkubo T, Furuichi Y, Umekawa H. Tryptophans 286 and 288 in the C-terminal region of protein B23.1 are important for its nucleolar localization. Biosci Biotechnol Biochem 2002; 66:2239–2242.[CrossRef][Medline] [Order article via Infotrieve] Wang W, Budhu A, Forgues M, Wang XW. Temporal and spatial control of nucleophosmin by the Ran-Crm1 complex in centrosome duplication. Nat Cell Biol 2005; 7:823–830.[CrossRef][Medline] [Order article via Infotrieve] Yu Y, Maggi LB Jr, Brady SN, et al. Nucleophosmin is essential for ribosomal protein L5 nuclear export. Mol Cell Biol 2006; 26:3798–3809.[Abstract/Free Full Text] Tokuyama Y, Horn HF, Kawamura K, Tarapore P, Fukasawa K. Specific phosphorylation of nucleophosmin on Thr(199) by cyclin-dependent kinase 2-cyclin E and its role in centrosome duplication. J Biol Chem 2001; 276:21529–21537.[Abstract/Free Full Text] Tarapore P, Shinmura K, Suzuki H, et al. Thr199 phosphorylation targets nucleophosmin to nuclear speckles and represses pre-mRNA processing. FEBS Lett 2006; 580:399–409.[CrossRef][Medline] [Order article via Infotrieve] Negi SS and Olson MO. Effects of interphase and mitotic phosphorylation on the mobility and location of nucleolar protein B23. J Cell Sci 2006; 119:3676–3685.[Abstract/Free Full Text] Dalenc F, Drouet J, Ader I, et al. Increased expression of a COOH-truncated nucleophosmin resulting from alternative splicing is associated with cellular resistance to ionizing radiation in HeLa cells. Int J Cancer 2002; 100:662–668.[CrossRef][Medline] [Order article via Infotrieve] Cordell JL, Pulford KA, Bigerna B, et al. Detection of normal and chimeric nucleophosmin in human cells. Blood 1999; 93:632–642.[Abstract/Free Full Text] Andersen JS, Lam YW, Leung AK, et al. Nucleolar proteome dynamics. Nature 2005; 433:77–83.[CrossRef][Medline] [Order article via Infotrieve] Lam YW, Trinkle-Mulcahy L, Lamond AI. The nucleolus. J Cell Sci 2005; 118:1335–1337.[Free Full Text] Spector DL, Ochs RL, Busch H. Silver staining, immunofluorescence, and immunoelectron microscopic localization of nucleolar phosphoproteins B23 and C23. Chromosoma 1984; 90:139–148.[CrossRef][Medline] [Order article via Infotrieve] Borer RA, Lehner CF, Eppenberger HM, Nigg EA. Major nucleolar proteins shuttle between nucleus and cytoplasm. Cell 1989; 56:379–390.[CrossRef][Medline] [Order article via Infotrieve] Yun JP, Chew EC, Liew CT, et al. Nucleophosmin/B23 is a proliferate shuttle protein associated with nuclear matrix. J Cell Biochem 2003; 90:1140–1148.[CrossRef][Medline] [Order article via Infotrieve] Herrera JE, Savkur R, Olson MO. The ribonuclease activity of nucleolar protein B23. Nucleic Acids Res 1995; 23:3974–3979.[Abstract/Free Full Text] Wang D, Baumann A, Szebeni A, Olson MO. The nucleic acid binding activity of nucleolar protein B23.1 resides in its carboxyl-terminal end. J Biol Chem 1994; 269:30994–30998.[Abstract/Free Full Text] Savkur RS and Olson MO. Preferential cleavage in pre-ribosomal RNA by protein B23 endoribonuclease. Nucleic Acids Res 1998; 26:4508–4515.[Abstract/Free Full Text] Feuerstein N, Chan PK, Mond JJ. Identification of numatrin, the nuclear matrix protein associated with induction of mitogenesis, as the nucleolar protein B23: implication for the role of the nucleolus in early transduction of mitogenic signals. J Biol Chem 1988; 263:10608–10612.[Abstract/Free Full Text] Li J, Sejas DP, Rani R, Koretsky T, Bagby GC, Pang Q. Nucleophosmin regulates cell cycle progression and stress response in hematopoietic stem/progenitor cells. J Biol Chem 2006; 281:16536–16545.[Abstract/Free Full Text] Grisendi S, Bernardi R, Rossi M, et al. Role of nucleophosmin in embryonic development and tumorigenesis. Nature 2005; 437:147–153.[CrossRef][Medline] [Order article via Infotrieve] Colombo E, Bonetti P, Lazzerini Denchi E, et al. Nucleophosmin is required for DNA integrity and p19Arf protein stability. Mol Cell Biol 2005; 25:8874–8886.[Abstract/Free Full Text] Lee SY, Park JH, Kim S, Park EJ, Yun Y, Kwon J. A proteomics approach for the identification of nucleophosmin and heterogeneous nuclear ribonucleoprotein C1/C2 as chromatin-binding proteins in response to DNA double-strand breaks. Biochem J 2005; 388:7–15.[CrossRef][Medline] [Order article via Infotrieve] Okuda M. The role of nucleophosmin in centrosome duplication. Oncogene 2002; 21:6170–6174.[CrossRef][Medline] [Order article via Infotrieve] Okuda M, Horn HF, Tarapore P, et al. Nucleophosmin/B23 is a target of CDK2/cyclin E in centrosome duplication. Cell 2000; 103:127–140.[CrossRef][Medline] [Order article via Infotrieve] Zhang H, Shi X, Paddon H, Hampong M, Dai W, Pelech S. B23/nucleophosmin serine 4 phosphorylation mediates mitotic functions of polo-like kinase 1. J Biol Chem 2004; 279:35726–35734.[Abstract/Free Full Text] Yao J, Fu C, Ding X, et al. Nek2A kinase regulates the localization of numatrin to centrosome in mitosis. FEBS Lett 2004; 575:112–118.[CrossRef][Medline] [Order article via Infotrieve] Budhu AS and Wang XW. Loading and unloading: orchestrating centrosome duplication and spindle assembly by Ran/Crm1. Cell Cycle 2005; 4:1510–1514.[Medline] [Order article via Infotrieve] Ye K. Nucleophosmin/B23, a multifunctional protein that can regulate apoptosis. Cancer Biol Ther 2005; 4:918–923.[CrossRef][Medline] [Order article via Infotrieve] Colombo E, Marine JC, Danovi D, Falini B, Pelicci PG. Nucleophosmin regulates the stability and transcriptional activity of p53. Nat Cell Biol 2002; 4:529–533.[CrossRef][Medline] [Order article via Infotrieve] Kurki S, Peltonen K, Laiho M. Nucleophosmin, HDM2 and p53: players in UV damage incited nucleolar stress response. Cell Cycle 2004; 3:976–979.[Medline] [Order article via Infotrieve] Maiguel DA, Jones L, Chakravarty D, Yang C, Carrier F. Nucleophosmin sets a threshold for p53 response to UV radiation. Mol Cell Biol 2004; 24:3703–3711.[Abstract/Free Full Text] Kurki S, Peltonen K, Latonen L, et al. Nucleolar protein NPM interacts with HDM2 and protects tumor suppressor protein p53 from HDM2-mediated degradation. Cancer Cell 2004; 5:465–475.[CrossRef][Medline] [Order article via Infotrieve] Rubbi CP and Milner J. p53: guardian of a genome's guardian? Cell Cycle 2003; 2:20–21.[Medline] [Order article via Infotrieve] Rubbi CP and Milner J. Disruption of the nucleolus mediates stabilization of p53 in response to DNA damage and other stresses. EMBO J 2003; 22:6068–6077.[CrossRef][Medline] [Order article via Infotrieve] Gao H, Jin S, Song Y, et al. B23 regulates GADD45a nuclear translocation and contributes to GADD45a-induced cell cycle G2-M arrest. J Biol Chem 2005; 280:10988–10996.[Abstract/Free Full Text] Bertwistle D, Sugimoto M, Sherr CJ. Physical and functional interactions of the Arf tumor suppressor protein with nucleophosmin/B23. Mol Cell Biol 2004; 24:985–996.[Abstract/Free Full Text] Itahana K, Bhat KP, Jin A, et al. Tumor suppressor ARF degrades B23, a nucleolar protein involved in ribosome biogenesis and cell proliferation. Mol Cell 2003; 12:1151–1164.[CrossRef][Medline] [Order article via Infotrieve] Kuo ML, den Besten W, Bertwistle D, Roussel MF, Sherr CJ. N-terminal polyubiquitination and degradation of the Arf tumor suppressor. Genes Dev 2004; 18:1862–1874.[Abstract/Free Full Text] Sherr CJ. Divorcing ARF and p53: an unsettled case. Nat Rev Cancer 2006; 6:663–673.[CrossRef][Medline] [Order article via Infotrieve] Zhang Y. The ARF-B23 connection: implications for growth control and cancer treatment. Cell Cycle 2004; 3:259–262.[Medline] [Order article via Infotrieve] Brady SN, Yu Y, Maggi LB Jr, Weber JD. ARF impedes NPM/B23 shuttling in an Mdm2-sensitive tumor suppressor pathway. Mol Cell Biol 2004; 24:9327–9338.[Abstract/Free Full Text] Korgaonkar C, Hagen J, Tompkins V, et al. Nucleophosmin (B23) targets ARF to nucleoli and inhibits its function. Mol Cell Biol 2005; 25:1258–1271.[Abstract/Free Full Text] Gjerset RA and Bandyopadhyay K. Regulation of p14ARF through subnuclear compartmentalization. Cell Cycle 2006; 5:686–690.[Medline] [Order article via Infotrieve] Lee C, Smith BA, Bandyopadhyay K, Gjerset RA. DNA damage disrupts the p14ARF-B23 (nucleophosmin) interaction and triggers a transient subnuclear redistribution of p14ARF. Cancer Res 2005; 65:9834–9842.[Abstract/Free Full Text] Chen D, Kon N, Li M, Zhang W, Qin J, Gu W. ARF-BP1/Mule is a critical mediator of the ARF tumor suppressor. Cell 2005; 121:1071–1083.[CrossRef][Medline] [Order article via Infotrieve] Falini B and Mason DY. Proteins encoded by genes involved in chromosomal alterations in lymphoma and leukemia: clinical value of their detection by immunocytochemistry. Blood 2002; 99:409–426.[Abstract/Free Full Text] Morris SW, Kirstein MN, Valentine MB, et al. Fusion of a kinase gene, ALK, to a nucleolar protein gene, NPM, in non-Hodgkin's lymphoma. Science 1994; 263:1281–1284.[Abstract/Free Full Text] Yoneda-Kato N, Look AT, Kirstein MN, et al. The t(3;5)(q25.1;q34) of myelodysplastic syndrome and acute myeloid leukemia produces a novel fusion gene, NPM-MLF1. Oncogene 1996; 12:265–275.[Medline] [Order article via Infotrieve] Redner RL, Rush EA, Faas S, Rudert WA, Corey SJ. The t(5;17) variant of acute promyelocytic leukemia expresses a nucleophosmin-retinoic acid receptor fusion. Blood 1996; 87:882–886.[Abstract/Free Full Text] Falini B, Pulford K, Pucciarini A, et al. Lymphomas expressing ALK fusion protein(s) other than NPM-ALK. Blood 1999; 94:3509–3515.[Abstract/Free Full Text] Ammatuna E, Noguera NI, Zangrilli D, et al. Rapid detection of nucleophosmin (NPM1) mutations in acute myeloid leukemia by denaturing HPLC. Clin Chem 2005; 51:2165–2167.[Free Full Text] Roti G, Rosati R, Bonasso R, et al. Denaturing high-performance liquid chromatography: a valid approach for identifying NPM1 mutations in acute myeloid leukemia. J Mol Diagn 2006; 8:254–259.[Abstract/Free Full Text] Noguera NI, Ammatuna E, Zangrilli D, et al. Simultaneous detection of NPM1 and FLT3-ITD mutations by capillary electrophoresis in acute myeloid leukemia. Leukemia 2005; 19:1479–1482.[CrossRef][Medline] [Order article via Infotrieve] Lin LI, Lin TC, Chou WC, Tang JL, Lin DT, Tien HF. A novel fluorescence-based multiplex PCR assay for rapid simultaneous detection of CEBPA mutations and NPM mutations in patients with acute myeloid leukemias. Leukemia 2006; 20:1899–1903.[CrossRef][Medline] [Order article via Infotrieve] Schnittger S, Schoch C, Kern W, et al. Nucleophosmin gene mutations are predictors of favorable prognosis in acute myelogenous leukemia with a normal karyotype. Blood 2005; 106:3733–3739.[Abstract/Free Full Text] Dohner K, Schlenk RF, Habdank M, et al. Mutant nucleophosmin (NPM1) predicts favorable prognosis in younger adults with acute myeloid leukemia and normal cytogenetics: interaction with other gene mutations. Blood 2005; 106:3740–3746.[Abstract/Free Full Text] Verhaak RG, Goudswaard CS, van Putten W, et al. Mutations in nucleophosmin (NPM1) in acute myeloid leukemia (AML): association with other gene abnormalities and previously established gene expression signatures and their favorable prognostic significance. Blood 2005; 106:3747–3754.[Abstract/Free Full Text] Thiede C, Koch S, Creutzig E, et al. Prevalence and prognostic impact of NPM1 mutations in 1485 adult patients with acute myeloid leukemia (AML). Blood 2006; 107:4011–4020.[Abstract/Free Full Text] Falini B, Martelli MP, Bolli N, et al. Immunohistochemistry predicts nucleophosmin (NPM) mutations in acute myeloid leukemia. Blood 2006; 108:1999–2005.[Abstract/Free Full Text] Bolli N, Galimberti S, Martelli MP, et al. Cytoplasmic nucleophosmin in myeloid sarcoma occurring 20 years after diagnosis of acute myeloid leukaemia. Lancet Oncol 2006; 7:350–352.[CrossRef][Medline] [Order article via Infotrieve] Caudill JS, Sternberg AJ, Li CY, Tefferi A, Lasho TL, Steensma DP. C-terminal nucleophosmin mutations are uncommon in chronic myeloid disorders. Br J Haematol 2006; 133:638–641.[CrossRef][Medline] [Order article via Infotrieve] Oki Y, Jelinek J, Beran M, Verstovsek S, Kantarjian HM, Issa JP. Mutations and promoter methylation status of NPM1 in myeloproliferative disorders. Haematologica 2006; 91:1147–1148.[Abstract/Free Full Text] Zhang Y, Zhang M, Yang L, Xiao Z. NPM1 mutations in myelodysplastic syndromes and acute myeloid leukemia with normal karyotype. Leuk Res 2007; 31:109–111.[CrossRef][Medline] [Order article via Infotrieve] Pasqualucci L, Liso A, Martelli MP, et al. Mutated nucleophosmin detects clonal multilineage involvement in acute myeloid leukemia: impact on WHO classification. Blood 2006; 108:4146–4155.[Abstract/Free Full Text] Chou WC, Tang JL, Lin LI, et al. Nucleophosmin mutations in de novo acute myeloid leukemia: the age-dependent incidences and the stability during disease evolution. Cancer Res 2006; 66:3310–3316.[Abstract/Free Full Text] Cazzaniga G, Dell'Oro MG, Mecucci C, et al. Nucleophosmin mutations in childhood acute myelogenous leukemia with normal karyotype. Blood 2005; 106:1419–1422.[Abstract/Free Full Text] Mullighan C, Kennedy A, Zhou X, Shurtleff S, Downing J. Pediatric acute myeloid leukemia with nuclephosmin mutations is characterized by a gene expression signature with disregulated HOX gene expression distinct from MLL-rearranged leukemias. ASH Meeting, Atlanta 2005; Abstract 2993. Suzuki T, Kiyoi H, Ozeki K, et al. Clinical characteristics and prognostic implications of NPM1 mutations in acute myeloid leukemia. Blood 2005; 106:2854–2861.[Abstract/Free Full Text] Boissel N, Renneville A, Biggio V, et al. Prevalence, clinical profile, and prognosis of NPM mutations in AML with normal karyotype. Blood 2005; 106:3618–3620.[Abstract/Free Full Text] Mariano AR, Colombo E, Luzi L, et al. Cytoplasmic localization of NPM in myeloid leukemias is dictated by gain-of-function mutations that create a functional nuclear export signal. Oncogene 2006; 25:4376–4380.[CrossRef][Medline] [Order article via Infotrieve] Albiero E, Madeo D, Giaretta I, Borghero C, Visco C, Rodeghiero F. A novel mutation in the exon 11 of nucleophosmin (NPM1) gene leads to a truncated form of the protein lacking the C-terminal NES-motif [abstract]. Haematologica 2006; 91:suppl 1, 237. Slovak ML, Kopecky KJ, Cassileth PA, et al. Karyotypic analysis predicts outcome of preremission and postremission therapy in adult acute myeloid leukemia: a Southwest Oncology Group/Eastern Cooperative Oncology Group Study. Blood 2000; 96:4075–4083.[Abstract/Free Full Text] Fenaux P, Jonveaux P, Quiquandon I, et al. p53 gene mutations in acute myeloid leukemia with 17p monosomy. Blood 1991; 78:1652–1657.[Abstract/Free Full Text] Wattel E, Preudhomme C, Hecquet B, et al. p53 mutations are associated with resistance to chemotherapy and short survival in hematologic malignancies. Blood 1994; 84:3148–3157.[Abstract/Free Full Text] Fukuda M, Asano S, Nakamura T, et al. CRM1 is responsible for intracellular transport mediated by the nuclear export signal. Nature 1997; 390:308–311.[CrossRef][Medline] [Order article via Infotrieve] Kau TR, Way JC, Silver PA. Nuclear transport and cancer: from mechanism to intervention. Nat Rev Cancer 2004; 4:106–117.[Medline] [Order article via Infotrieve] Bogerd HP, Fridell RA, Benson RE, Hua J, Cullen BR. Protein sequence requirements for function of the human T-cell leukemia virus type 1 Rex nuclear export signal delineated by a novel in vivo randomization-selection assay. Mol Cell Biol 1996; 16:4207–4214.[Abstract] Kutay U and Guttinger S. Leucine-rich nuclear-export signals: born to be weak. Trends Cell Biol 2005; 15:121–124.[CrossRef][Medline] [Order article via Infotrieve] Engelsma D, Bernad R, Calafat J, Fornerod M. Supraphysiological nuclear export signals bind CRM1 independently of RanGTP and arrest at Nup358. EMBO J 2004; 23:3643–3652.[CrossRef][Medline] [Order article via Infotrieve] Falini B, Bolli N, Shan J, et al. Both carboxy-terminus NES motif and mutated tryptophan(s) are crucial for aberrant nuclear export of nucleophosmin leukemic mutants in NPMc+ AML. Blood 2006; 107:4514–4523.[Abstract/Free Full Text] Nakagawa M, Kameoka Y, Suzuki R. Nucleophosmin in acute myelogenous leukemia [letter]. N Engl J Med 2005; 352:1819–1820.[Free Full Text] Meissner T, Krause E, Vinkemeier U. Ratjadone and leptomycin B block CRM1-dependent nuclear export by identical mechanisms. FEBS Lett 2004; 576:27–30.[CrossRef][Medline] [Order article via Infotrieve] Henderson BR and Eleftheriou A. A comparison of the activity, sequence specificity, and CRM1-dependence of different nuclear export signals. Exp Cell Res 2000; 256:213–224.[CrossRef][Medline] [Order article via Infotrieve] la Cour T, Gupta R, Rapacki K, Skriver K, Poulsen FM, Brunak S. NESbase version 1.0: a database of nuclear export signals. Nucleic Acids Res 2003; 31:393–396.[Abstract/Free Full Text] den Besten W, Kuo ML, Williams RT, Sherr CJ. Myeloid leukemia-associated nucleophosmin mutants perturb p53-dependent and independent activities of the Arf tumor suppressor protein. Cell Cycle 2005; 4:1593–1598.[Medline] [Order article via Infotrieve] Bischof D, Pulford K, Mason DY, Morris SW. Role of the nucleophosmin (NPM) portion of the non-Hodgkin's lymphoma-associated NPM-anaplastic lymphoma kinase fusion protein in oncogenesis. Mol Cell Biol 1997; 17:2312–2325.[Abstract] Falini B, Bigerna B, Pucciarini A, et al. Aberrant subcellular expression of nucleophosmin and NPM-MLF1 fusion protein in acute myeloid leukaemia carrying t(3;5): a comparison with NPMc+ AML. Leukemia 2006; 20:368–371.[CrossRef][Medline] [Order article via Infotrieve] Colombo E, Martinelli P, Zamponi R, et al. Delocalization and destabilization of the Arf tumor suppressor by the leukemia-associated NPM mutant. Cancer Res 2006; 66:3044–3050.[Abstract/Free Full Text] Grisendi S, Mecucci C, Falini B, Pandolfi PP. Nucleophosmin and cancer. Nat Rev Cancer 2006; 6:493–505.[CrossRef][Medline] [Order article via Infotrieve] Gallagher SJ, Kefford RF, Rizos H. The ARF tumour suppressor. Int J Biochem Cell Biol 2006; 38:1637–1641.[CrossRef][Medline] [Order article via Infotrieve] Chen W, Rassidakis GZ, Li J, et al. High frequency of NPM1 gene mutations in acute myeloid leukemia with prominent nuclear invaginations ("cuplike" nuclei). Blood 2006; 108:1783–1784.[Free Full Text] Bernell P, Jacobsson B, Nordgren A, Hast R. Clonal cell lineage involvement in myelodysplastic syndromes studied by fluorescence in situ hybridization and morphology. Leukemia 1996; 10:662–668.[Medline] [Order article via Infotrieve] Van den Berghe H, Vermaelen K, Mecucci C, Barbieri D, Tricot G. The 5q-anomaly. Cancer Genet Cytogenet 1985; 17:189–255.[CrossRef][Medline] [Order article via Infotrieve] Delaunay J, Vey N, Leblanc T, et al. Prognosis of inv(16)/t(16;16) acute myeloid leukemia (AML): a survey of 110 cases from the French AML Intergroup. Blood 2003; 102:462–469.[Abstract/Free Full Text] Nguyen S, Leblanc T, Fenaux P, et al. A white blood cell index as the main prognostic factor in t(8;21) acute myeloid leukemia (AML): a survey of 161 cases from the French AML Intergroup. Blood 2002; 99:3517–3523.[Abstract/Free Full Text] Preudhomme C, Sagot C, Boissel N, et al. Favorable prognostic significance of CEBPA mutations in patients with de novo acute myeloid leukemia: a study from the Acute Leukemia French Association (ALFA). Blood 2002; 100:2717–2723.[Abstract/Free Full Text] Gallagher R. Duelling mutations in normal karyotype AML. Blood 106:3681–3682. Choudhary C, Schwable J, Brandts C, et al. AML-associated Flt3 kinase domain mutations show signal transduction differences compared with Flt3 ITD mutations. Blood 2005; 106:265–273.[Abstract/Free Full Text] Li J, Zhang X, Sejas DP, Pang Q. Negative regulation of p53 by nucleophosmin antagonizes stress-induced apoptosis in human normal and malignant hematopoietic cells. Leuk Res 2005; 29:1415–1423.[CrossRef][Medline] [Order article via Infotrieve] Chan PK and Chan FY. A study of correlation between NPM-translocation and apoptosis in cells induced by daunomycin. Biochem Pharmacol 1999; 57:1265–1273.[CrossRef][Medline] [Order article via Infotrieve] Gorello P, Cazzaniga G, Alberti F, et al. Quantitative assessment of minimal residual disease in acute myeloid leukemia carrying nucleophosmin (NPM1) gene mutations. Leukemia 2006; 20:1103–1108.[CrossRef][Medline] [Order article via Infotrieve] Adolfsson J, Mansson R, Buza-Vidas N, et al. Identification of Flt3+ lympho-myeloid stem cells lacking erythro-megakaryocytic potential a revised road map for adult blood lineage commitment. Cell 2005; 121:295–306.[CrossRef][Medline] [Order article via Infotrieve] Alcalay M, Tiacci E, Bergomas R, et al. Acute myeloid leukemia bearing cytoplasmic nucleophosmin (NPMc+ AML) shows a distinct gene expression profile characterized by up-regulation of genes involved in stem-cell maintenance. Blood 2005; 106:899–902.[Abstract/Free Full Text] Mrozek K, Marcucci G, Paschka P, Whitman SP, Bloomfield CD. Clinical relevance of mutations and gene-expression changes in adult acute myeloid leukemia with normal cytogenetics: are we ready for a prognostically prioritized molecular classification? Blood Prepublished on September 7, 2006, as DOI 10.1182/blood-2006-06-001149.[Abstract/Free Full Text] Bardet V, Costa LD, Elie C, et al. Nucleophosmin status may influence the therapeutic decision in de novo acute myeloid leukemia with normal karyotype. Leukemia 2006; 20:1644–1646.[CrossRef][Medline] [Order article via Infotrieve] Quentmeier H, Martelli MP, Dirks WG, et al. Cell line OCI/AML3 bears exon-12 NPM gene mutation-A and cytoplasmic expression of nucleophosmin. Leukemia 2005; 19:1760–1767.[CrossRef][Medline] [Order article via Infotrieve] CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this? This article has been cited by other articles: C. Haferlach, M. Vignetti, T. Haferlach, and B. Falini Response: NPM1-mutated AML is an entity irrespective of whether or not chromosomal aberrations are present Blood, November 12, 2009; 114(20): 4602 - 4603. [Full Text] [PDF] C. Haferlach, C. Mecucci, S. Schnittger, A. Kohlmann, M. Mancini, A. Cuneo, N. Testoni, G. Rege-Cambrin, A. Santucci, M. Vignetti, et al. AML with mutated NPM1 carrying a normal or aberrant karyotype show overlapping biologic, pathologic, immunophenotypic, and prognostic features Blood, October 1, 2009; 114(14): 3024 - 3032. [Abstract] [Full Text] [PDF] S. Schnittger, W. Kern, C. Tschulik, T. Weiss, F. Dicker, B. Falini, C. Haferlach, and T. Haferlach Minimal residual disease levels assessed by NPM1 mutation-specific RQ-PCR provide important prognostic information in AML Blood, September 10, 2009; 114(11): 2220 - 2231. [Abstract] [Full Text] [PDF] F. Scaloni, S. Gianni, L. Federici, B. Falini, and M. Brunori Folding mechanism of the C-terminal domain of nucleophosmin: residual structure in the denatured state and its pathophysiological significance FASEB J, August 1, 2009; 23(8): 2360 - 2365. [Abstract] [Full Text] [PDF] I. H. I. M. Hollink, M. M. van den Heuvel-Eibrink, M. Zimmermann, B. V. Balgobind, S. T. C. J. M. Arentsen-Peters, M. Alders, A. Willasch, G. J. L. Kaspers, J. Trka, A. Baruchel, et al. Clinical relevance of Wilms tumor 1 gene mutations in childhood acute myeloid leukemia Blood, June 4, 2009; 113(23): 5951 - 5960. [Abstract] [Full Text] [PDF] U. Bacher, A. Kohlmann, and T. Haferlach Perspectives of gene expression profiling for diagnosis and therapy in haematological malignancies Brief Funct Genomic Proteomic, May 27, 2009; (2009) elp011v1. [Abstract] [Full Text] [PDF] F. Schneider, E. Hoster, M. Unterhalt, S. Schneider, A. Dufour, T. Benthaus, G. Mellert, E. Zellmeier, S. K. Bohlander, M. Feuring-Buske, et al. NPM1 but not FLT3-ITD mutations predict early blast cell clearance and CR rate in patients with normal karyotype AML (NK-AML) or high-risk myelodysplastic syndrome (MDS) Blood, May 21, 2009; 113(21): 5250 - 5253. [Abstract] [Full Text] [PDF] F. Facchetti, S. A. Pileri, C. Agostinelli, M. P. Martelli, M. Paulli, A. Venditti, M. F Martelli, and B. Falini Cytoplasmic nucleophosmin is not detected in blastic plasmacytoid dendritic cell neoplasm Haematologica, February 1, 2009; 94(2): 285 - 288. [Abstract] [Full Text] [PDF] G. Meloni, M. Mancini, V. Gianfelici, M. P. Martelli, R. Foa, and B. Falini Late relapse of acute myeloid leukemia with mutated NPM1 after eight years: evidence of NPM1 mutation stability Haematologica, February 1, 2009; 94(2): 298 - 300. [Full Text] [PDF] T. Akagi, S. Ogawa, M. Dugas, N. Kawamata, G. Yamamoto, Y. Nannya, M. Sanada, C. W. Miller, A. Yung, S. Schnittger, et al. Frequent genomic abnormalities in acute myeloid leukemia/myelodysplastic syndrome with normal karyotype Haematologica, February 1, 2009; 94(2): 213 - 223. [Abstract] [Full Text] [PDF] M. P. Martelli, V. Pettirossi, E. Bonifacio, F. Mezzasoma, N. Manes, D. Cecchini, M. Capanni, I. Gionfriddo, A. Liso, R. Pacini, et al. Evidence for CD34+ Hematopoietic Progenitor Cell Involvement in Acute Myeloid Leukemia with NPM1 Gene Mutation: Implications for the Cell of Origin Blood (ASH Annual Meeting Abstracts), November 16, 2008; 112(11): 307 - 307. [Abstract] [Full Text] A. Liso, F. Castiglione, A. Cappuccio, F. Stracci, R. F. Schlenk, S. Amadori, C. Thiede, S. Schnittger, P. J.M. Valk, K. Dohner, et al. A one-mutation mathematical model can explain the age incidence of acute myeloid leukemia with mutated nucleophosmin (NPM1) Haematologica, August 1, 2008; 93(8): 1219 - 1226. [Abstract] [Full Text] [PDF] T. S. Laughlin, M. W. Becker, J. L. Liesveld, D. A. Mulford, C. N. Abboud, P. Brown, and P. G. Rothberg Rapid Method for Detection of Mutations in the Nucleophosmin Gene in Acute Myeloid Leukemia J. Mol. Diagn., July 1, 2008; 10(4): 338 - 345. [Abstract] [Full Text] [PDF] F. Lo-Coco, A. Cuneo, F. Pane, D. Cilloni, D. Diverio, M. Mancini, N. Testoni, A. Bardi, B. Izzo, N. Bolli, et al. Prognostic impact of genetic characterization in the GIMEMA LAM99P multicenter study for newly diagnosed acute myeloid leukemia Haematologica, July 1, 2008; 93(7): 1017 - 1024. [Abstract] [Full Text] [PDF] M. Jongen-Lavrencic, S. M. Sun, M. K. Dijkstra, P. J. M. Valk, and B. Lowenberg MicroRNA expression profiling in relation to the genetic heterogeneity of acute myeloid leukemia Blood, May 15, 2008; 111(10): 5078 - 5085. [Abstract] [Full Text] [PDF] T. Ottone, E. Ammatuna, S. Lavorgna, N. I. Noguera, F. Buccisano, A. Venditti, L. Gianni, M. Postorino, G. Federici, S. Amadori, et al. An Allele-Specific RT-PCR Assay to Detect Type A Mutation of the Nucleophosmin-1 Gene in Acute Myeloid Leukemia J. Mol. Diagn., May 1, 2008; 10(3): 212 - 216. [Abstract] [Full Text] [PDF] G. Wertheim and A. Bagg Nucleophosmin (NPM1) Mutations in Acute Myeloid Leukemia: An Ongoing (Cytoplasmic) Tale of Dueling Mutations and Duality of Molecular Genetic Testing Methodologies J. Mol. Diagn., May 1, 2008; 10(3): 198 - 202. [Abstract] [Full Text] [PDF] P. Szankasi, M. Jama, and D. W. Bahler A New DNA-Based Test for Detection of Nucleophosmin Exon 12 Mutations by Capillary Electrophoresis J. Mol. Diagn., May 1, 2008; 10(3): 236 - 241. [Abstract] [Full Text] [PDF] B. Falini, M. P. Martelli, C. Mecucci, A. Liso, N. Bolli, B. Bigerna, A. Pucciarini, S. Pileri, G. Meloni, M. F. Martelli, et al. Cytoplasmic mutated nucleophosmin is stable in primary leukemic cells and in a xenotransplant model of NPMc+ acute myeloid leukemia in SCID mice Haematologica, May 1, 2008; 93(5): 775 - 779. [Abstract] [Full Text] [PDF] R. Garzon, M. Garofalo, M. P. Martelli, R. Briesewitz, L. Wang, C. Fernandez-Cymering, S. Volinia, C.-G. Liu, S. Schnittger, T. Haferlach, et al. Distinctive microRNA signature of acute myeloid leukemia bearing cytoplasmic mutated nucleophosmin PNAS, March 11, 2008; 105(10): 3945 - 3950. [Abstract] [Full Text] [PDF] B. Falini, C. Mecucci, G. Saglio, F. L. Coco, D. Diverio, P. Brown, F. Pane, M. Mancini, M. P. Martelli, S. Pileri, et al. NPM1 mutations and cytoplasmic nucleophosmin are mutually exclusive of recurrent genetic abnormalities: a comparative analysis of 2562 patients with acute myeloid leukemia Haematologica, March 1, 2008; 93(3): 439 - 442. [Abstract] [Full Text] [PDF] R. E. Gale, C. Green, C. Allen, A. J. Mead, A. K. Burnett, R. K. Hills, D. C. Linch, and on behalf of the Medical Research Council Adult Le The impact of FLT3 internal tandem duplication mutant level, number, size, and interaction with NPM1 mutations in a large cohort of young adult patients with acute myeloid leukemia Blood, March 1, 2008; 111(5): 2776 - 2784. [Abstract] [Full Text] [PDF] F. P. Kroschinsky, U. Schakel, R. Fischer, B. Mohr, U. Oelschlaegel, R. Repp, M. Schaich, S. Soucek, G. Baretton, G. Ehninger, et al. Cup-like acute myeloid leukemia: new disease or artificial phenomenon? Haematologica, February 1, 2008; 93(2): 283 - 286. [Abstract] [Full Text] [PDF] T. Haferlach Molecular Genetic Pathways as Therapeutic Targets in Acute Myeloid Leukemia Hematology, January 1, 2008; 2008(1): 400 - 411. [Abstract] [Full Text] [PDF] V. P. S. Rawat, S. Thoene, V. M. Naidu, N. Arseni, B. Heilmeier, K. Metzeler, K. Petropoulos, A. Deshpande, L. Quintanilla-Martinez, S. K. Bohlander, et al. Overexpression of CDX2 perturbs HOX gene expression in murine progenitors depending on its N-terminal domain and is closely correlated with deregulated HOX gene expression in human acute myeloid leukemia Blood, January 1, 2008; 111(1): 309 - 319. [Abstract] [Full Text] [PDF] W. Zhang, J.-M. Navenot, N. M. Frilot, N. Fujii, and S. C. Peiper Association of Nucleophosmin Negatively Regulates CXCR4-Mediated G Protein Activation and Chemotaxis Mol. Pharmacol., November 1, 2007; 72(5): 1310 - 1321. [Abstract] [Full Text] [PDF] N. Bolli, I. Nicoletti, M. F. De Marco, B. Bigerna, A. Pucciarini, R. Mannucci, M. P. Martelli, A. Liso, C. Mecucci, F. Fabbiano, et al. Born to Be Exported: COOH-Terminal Nuclear Export Signals of Different Strength Ensure Cytoplasmic Accumulation of Nucleophosmin Leukemic Mutants Cancer Res., July 1, 2007; 67(13): 6230 - 6237. [Abstract] [Full Text] [PDF] B. Falini, I. Nicoletti, N. Bolli, M. P. Martelli, A. Liso, P. Gorello, F. Mandelli, C. Mecucci, and M. F. Martelli Translocations and mutations involving the nucleophosmin (NPM1) gene in lymphomas and leukemias Haematologica, April 1, 2007; 92(4): 519 - 532. [Abstract] [Full Text] [PDF] H. Dohner Implication of the Molecular Characterization of Acute Myeloid Leukemia Hematology, January 1, 2007; 2007(1): 412 - 419. [Abstract] [Full Text] [PDF] This Article Abstract Full Text (PDF) All Versions of this Article: blood-2006-07-012252v1 blood-2006-07-012252v2 109/3/874    most recent Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Rights and Permissions Citing Articles Citing Articles via HighWire Citing Articles via CrossRef Citing Articles via Google Scholar Google Scholar Articles by Falini, B. Articles by Mecucci, C. Search for Related Content PubMed PubMed Citation Articles by Falini, B. Articles by Mecucci, C. Related Collections Neoplasia Oncogenes and Tumor Suppressors Free Research Articles Review Articles Social Bookmarking                   What's this?

	Copyright © 2007 by American Society of Hematology         Online ISSN: 1528-0020